Lonza Earnings Miss

Lonza sets new mid-term targets, confirms 2026 outlook

Lonza confirmed its 2026 outlook and set new mid-term targets, planning to sell its Capsules & Health Ingredients business for $3 billion to become a pure-play drug manufacturer, targeting 10% to 13%